Example: confidence
NDA 021470 Finacea Gel FDA Approved 5 August …
NDA 021470 Finacea Gel FDA Approved 5 August 2016.doc 6.2 Post-Marketing Experience The following adverse reactions have been identified post approval of FINACEA Gel.
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KYLEENA safely and effectively. See full prescribing information …
NDA 203159 Skyla FDA Approved 1 Mar 2018 1
labeling.bayerhealthcare.comNDA 203159 Skyla FDA Approved 1 Mar 2018 2
FDA-Approved Patient Labeling Patient …
labeling.bayerhealthcare.comNDA 21225 Mirena FDA Approved 08 June 2017 FDA-Approved Patient Labeling Patient Information Mirena® (mur-ā-nah) (levonorgestrel-releasing intrauterine system)
When you’re done having children, condersi Essure
labeling.bayerhealthcare.com6 7 1YOUR YCMPLELRTOGILDRHSLR®VVOULRiUYsLIOUL You should speak to your doctor if: • You are taking or receiving therapy that suppresses your immune system Examples include
HIGHLIGHTS OF PRESCRIBING INFORMATION than …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YAZ safely and effectively. See full …
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NEXAVAR safely and effectively. See full prescribing information for NEXAVAR.
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YASMIN safely and effectively. See full prescribing information …
myBETAapp™ Instructions for Use - Bayer HealthCare
labeling.bayerhealthcare.com1 myBETAapp™ Instructions for Use Contents 1 Overview of myBETAapp ..... 1
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.bayerhealthcare.comNDA 21225 Mirena FDA Approved 08 June 2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.bayerhealthcare.com2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE KOVALTRY, Antihemophilic Factor (Recombinant), is a recombinant, human …
Related documents
Reference ID: 3366104 - ZEVALIN® (ibritumomab …
www.zevalin.comfull prescribing information warning: serious infusion reactions, prolonged and severe cytopenias, and severe cutaneous and mucocutaneous reactions
HYDRODIURIL (HYDROCHLOROTHIAZIDE)
www.hypertensionmeds.comHydroDIURIL® (Hydrochlorothiazide) 7897450 4 ADVERSE REACTIONS The following adverse reactions have been reported and, within each category, are listed in order of ...
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.astellas.us4 5 WARNINGS AND PRECAUTIONS 5.1 Hepatic Adverse Drug Reactions Hepatic adverse drug reactions (e.g., elevations in alanine aminotransferase (ALT), …
Reference ID: 3340037 - Food and Drug …
www.accessdata.fda.govsevere or worsening liver tests. (2.3, 5.4) prolonged cutaneous r
NEW ZEALAND DATA SHEET 1. FENPAED ORAL …
www.medsafe.govt.nzCombination use of ACE inhibitors or angiotensin receptor antagonists, antiinflammatory drugs and thiazide diuretics The use of an ACE inhibiting drug (ACE-inhibitor or angiotensin receptor antagonist, an anti-
NEW ZEALAND DATA SHEET 1. MAXIGESIC TABLET
www.medsafe.govt.nzoccur without warning. These serious adverse events are idiosyncratic and are independent of dose or duration of use. Patients should be advised of the signs and symptoms of serious skin
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
media.celgene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ABRAXANE safely and effectively. See full prescribing
DRUG NAME: SUNItinib - BC Cancer
www.bccancer.bc.cacross blood brain barrier? animal studies suggest that SUNItinib is able to cross the blood brain barrier : volume of distribution . 2230 L : Distribution